Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
Public ClinicalTrials.gov record NCT01077518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
Study identification
- NCT ID
- NCT01077518
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 346 participants
Conditions and interventions
Conditions
Interventions
- Ofatumumab Drug
- Bendamustine infusion Drug
- Ofatumumab and Bendamustine infusions (Arm A) Drug
- Bendamustine infusion (Arm B) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2010
- Primary completion
- Jan 2, 2018
- Completion
- Dec 25, 2018
- Last update posted
- Mar 26, 2020
2010 – 2018
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Tucson | Arizona | 85715 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Palm Springs | California | 92262 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20037 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30341 | — |
| Novartis Investigative Site | Coeur d'Alene | Idaho | 83814 | — |
| Novartis Investigative Site | Silver Spring | Maryland | 21044 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | St Louis | Missouri | 63141 | — |
| Novartis Investigative Site | Mineola | New York | 11501 | — |
| Novartis Investigative Site | Rochester | New York | 14642 | — |
| Novartis Investigative Site | Danville | Pennsylvania | 17822 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19106 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29425 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Richmond | Virginia | 23230 | — |
| Novartis Investigative Site | Seattle | Washington | 98108 | — |
| Novartis Investigative Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01077518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01077518 live on ClinicalTrials.gov.